RxDoctor Payments Data

James Maisel, MD

Ophthalmology · Hicksville, NYNPI 1720009525

Payments from drug & device makers

$25,288in general payments, 2019–2025

Across 110 payments — averaging $229.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$13K
  • AbbVie$7K
  • Astellas Pharma US Inc$3K
  • Genentech USA, Inc.$664
  • Apellis Pharmaceuticals, Inc.$283
  • Tarsus Pharmaceuticals, Inc.$246
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$20,62282%
  • Travel & lodging$2421%
  • Food & beverage$4,42417%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,288 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$5,251,944
Medicare patients
935
Services billed
96,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate18$7,967
LumiganBimatoprost12$6,906
Bromfenac Sodium21$2,999
Brimonidine Tartrate19$2,560
Difluprednate21$2,012
Latanoprost87$1,528
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat87$1,501
Prednisolone Acetate15$1,120
Dorzolamide Hcl17$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$6,749$6,90612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Hicksville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →